In turn, Hwang et al. (2012) assessed prognostic influence of BCL-2 expression in the group of 7,230 primary BC patients in clinical stage 1, 2 or 3, of whom 4,532 received different systemic therapy. The gene discussed is BCL2; the disease is breast cancer.